IDH1 and central nervous system cancer: First, IDH1 mutation results in dramatically elevated levels of 2HG, a potential oncometabolite, which could influence the whole metabolic profile.[34] Secondly, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype, which is a powerful determinant of tumor pathogenicity [35].